FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2018856880> ?p ?o ?g. }

• W2018856880 endingPage "890" @default.
• W2018856880 startingPage "885" @default.
• W2018856880 abstract "The European Randomized Study of Screening for Prostate Cancer (ERSPC) has shown a 21% reduction in prostate cancer (PCa) mortality and a 1.6-fold increase in PCa incidence with prostate-specific antigen (PSA)-based screening (at 13 yr of follow-up). We evaluated PCa incidence by risk category at diagnosis across the study arms to assess the potential impact on PCa mortality.Information on arm, centre, T and M stage, Gleason score, serum PSA at diagnosis, age at randomisation, follow-up time, and vital status were extracted from the ERSPC database. Four risk categories at diagnosis were defined: 1, low; 2, intermediate; 3, high; 4, metastatic disease. PSA (≤100 or >100 ng/ml) was used as the indicator of metastasis.Incidence rate ratios (IRRs) for screening versus control arm by risk category at diagnosis and follow-up time were calculated using Poisson regression analysis for seven centres. Follow-up was truncated at 13 yr. Missing data were imputed using chained equations. The analyses were carried out on an intention-to-treat basis.In the screening arm, 7408 PCa cases were diagnosed and 6107 in the control arm. The proportion of missing stage, Gleason score, or PSA value was comparable in the two arms (8% vs 10%), but differed among centres. The IRRs were elevated in the screening arm for the low-risk (IRR: 2.14; 95% CI, 2.03-2.25) and intermediate-risk (IRR: 1.24; 95% CI, 1.16-1.34) categories at diagnosis, equal to unity for the high-risk category at diagnosis (IRR: 1.00; 95% CI, 0.89-1.13), and reduced for metastatic disease at diagnosis (IRR: 0.60; 95% CI, 0.52-0.70). The IRR of metastatic disease had temporal pattern similar to mortality, shifted forwards an average of almost 3 yr, although the mortality reduction was smaller.The results confirm a reduction in metastatic disease at diagnosis in the screening arm, preceding mortality reduction by almost 3 yr.The findings of this study indicate that the decrease in metastatic disease at diagnosis is the major determinant of the prostate cancer mortality reduction in the European Randomized study of Screening for Prostate Cancer." @default.
• W2018856880 created "2016-06-24" @default.
• W2018856880 creator A5001534857 @default.
• W2018856880 creator A5011425417 @default.
• W2018856880 creator A5018829875 @default.
• W2018856880 creator A5022649819 @default.
• W2018856880 creator A5023799961 @default.
• W2018856880 creator A5029422912 @default.
• W2018856880 creator A5033709973 @default.
• W2018856880 creator A5037303670 @default.
• W2018856880 creator A5039867286 @default.
• W2018856880 creator A5041240078 @default.
• W2018856880 creator A5041970634 @default.
• W2018856880 creator A5046400409 @default.
• W2018856880 creator A5046426052 @default.
• W2018856880 creator A5049580074 @default.
• W2018856880 creator A5064546314 @default.
• W2018856880 creator A5074228817 @default.
• W2018856880 creator A5075326056 @default.
• W2018856880 creator A5078025092 @default.
• W2018856880 creator A5087481089 @default.
• W2018856880 creator A5089884074 @default.
• W2018856880 date "2015-11-01" @default.
• W2018856880 modified "2023-10-18" @default.
• W2018856880 title "Metastatic Prostate Cancer Incidence and Prostate-specific Antigen Testing: New Insights from the European Randomized Study of Screening for Prostate Cancer" @default.
• W2018856880 cites W1994121126 @default.
• W2018856880 cites W2055624097 @default.
• W2018856880 cites W2077387602 @default.
• W2018856880 cites W2095761465 @default.
• W2018856880 cites W2097336603 @default.
• W2018856880 cites W2098580343 @default.
• W2018856880 cites W2100358124 @default.
• W2018856880 cites W2106058419 @default.
• W2018856880 cites W2115817599 @default.
• W2018856880 cites W2120357482 @default.
• W2018856880 cites W2134843796 @default.
• W2018856880 cites W2153276620 @default.
• W2018856880 cites W2157177481 @default.
• W2018856880 cites W2167662494 @default.
• W2018856880 cites W4231292595 @default.
• W2018856880 doi "https://doi.org/10.1016/j.eururo.2015.02.042" @default.
• W2018856880 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4982869" @default.
• W2018856880 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25791513" @default.
• W2018856880 hasPublicationYear "2015" @default.
• W2018856880 type Work @default.
• W2018856880 sameAs 2018856880 @default.
• W2018856880 citedByCount "105" @default.
• W2018856880 countsByYear W20188568802015 @default.
• W2018856880 countsByYear W20188568802016 @default.
• W2018856880 countsByYear W20188568802017 @default.
• W2018856880 countsByYear W20188568802018 @default.
• W2018856880 countsByYear W20188568802019 @default.
• W2018856880 countsByYear W20188568802020 @default.
• W2018856880 countsByYear W20188568802021 @default.
• W2018856880 countsByYear W20188568802022 @default.
• W2018856880 countsByYear W20188568802023 @default.
• W2018856880 crossrefType "journal-article" @default.
• W2018856880 hasAuthorship W2018856880A5001534857 @default.
• W2018856880 hasAuthorship W2018856880A5011425417 @default.
• W2018856880 hasAuthorship W2018856880A5018829875 @default.
• W2018856880 hasAuthorship W2018856880A5022649819 @default.
• W2018856880 hasAuthorship W2018856880A5023799961 @default.
• W2018856880 hasAuthorship W2018856880A5029422912 @default.
• W2018856880 hasAuthorship W2018856880A5033709973 @default.
• W2018856880 hasAuthorship W2018856880A5037303670 @default.
• W2018856880 hasAuthorship W2018856880A5039867286 @default.
• W2018856880 hasAuthorship W2018856880A5041240078 @default.
• W2018856880 hasAuthorship W2018856880A5041970634 @default.
• W2018856880 hasAuthorship W2018856880A5046400409 @default.
• W2018856880 hasAuthorship W2018856880A5046426052 @default.
• W2018856880 hasAuthorship W2018856880A5049580074 @default.
• W2018856880 hasAuthorship W2018856880A5064546314 @default.
• W2018856880 hasAuthorship W2018856880A5074228817 @default.
• W2018856880 hasAuthorship W2018856880A5075326056 @default.
• W2018856880 hasAuthorship W2018856880A5078025092 @default.
• W2018856880 hasAuthorship W2018856880A5087481089 @default.
• W2018856880 hasAuthorship W2018856880A5089884074 @default.
• W2018856880 hasBestOaLocation W20188568802 @default.
• W2018856880 hasConcept C120665830 @default.
• W2018856880 hasConcept C121332964 @default.
• W2018856880 hasConcept C121608353 @default.
• W2018856880 hasConcept C126322002 @default.
• W2018856880 hasConcept C126894567 @default.
• W2018856880 hasConcept C143998085 @default.
• W2018856880 hasConcept C146357865 @default.
• W2018856880 hasConcept C151730666 @default.
• W2018856880 hasConcept C2775941076 @default.
• W2018856880 hasConcept C2776235491 @default.
• W2018856880 hasConcept C2780192828 @default.
• W2018856880 hasConcept C2781406297 @default.
• W2018856880 hasConcept C2908647359 @default.
• W2018856880 hasConcept C29456083 @default.
• W2018856880 hasConcept C61511704 @default.
• W2018856880 hasConcept C71924100 @default.
• W2018856880 hasConcept C73269764 @default.
• W2018856880 hasConcept C86803240 @default.
• W2018856880 hasConcept C99454951 @default.
• W2018856880 hasConceptScore W2018856880C120665830 @default.

• next